# US 2021/0079082 A1 · C-terminal antibody variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079082 A1
- Document ID: US20210079082A1
- Status: Published application
- Kind: A1
- Application number: 16/971,590
- Filed: 2019-03-29
- Published: 2021-03-18
- Earliest claimed: 2018-03-30
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Zhe Huang; Jennitte LeAnn Stevens; Greg Flynn; Szilan Fodor; Mark Daris
- Web page: https://patentgrep.com/patent/US20210079082A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 19/10: for osteoporosis
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention generally relates to anti-sclerostin antibodies having C-terminal modifications, and compositions comprising such antibodies.

## Claims

### Claim 1

An antibody that specifically binds to sclerostin of SEQ ID NO: 1 and comprises a set of six CDRs set forth in SEQ ID NOs: 2-7, wherein the antibody comprises a heavy chain comprising the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO: 8) at the C-terminus of the heavy chain.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 9 and a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 10.

### Claim 3 (depends on 1, 2)

The antibody of claim 1 or claim 2, wherein the C-terminus of the heavy chain is amidated.

### Claim 4 (depends on 1, 2, 3)

The antibody of any one of claims 1-3, wherein the C-terminus of both heavy chains comprises the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO: 8).

### Claim 5 (depends on 4)

The antibody of claim 4, wherein the C-terminus of both heavy chains is amidated.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody of any one of claims 1-5, comprising the light chain amino acid sequence set forth in SEQ ID NO: 12 and the heavy chain amino acid sequence set forth in SEQ ID NO: 13.

### Claim 7 (depends on 1, 2)

The antibody of claim 1 or claim 2, wherein the antibody comprises a sequence of amino acids comprising Pro-Ala-Arg-Gly-Lys (SEQ ID NO: 11) at the C-terminus of a heavy chain.

### Claim 8 (depends on 7)

The antibody of claim 7, comprising the light chain amino acid sequence set forth in SEQ ID NO: 12 and the heavy chain amino acid sequence set forth in SEQ ID NO: 14.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutical composition comprising a population of antibodies of any one of claims 1-8 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutical composition comprising a mixture of antibodies that specifically bind to sclerostin of SEQ ID NO: 1 and a pharmaceutically acceptable carrier;
wherein about 3-5% of the antibodies in the composition are a population of antibodies of any one of claims 1-8.

### Claim 11 (depends on 9, 10)

The pharmaceutical composition of claim 9 or claim 10, wherein all or part of the population of antibodies comprise a single heavy chain comprising a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence.

### Claim 12 (depends on 9, 10)

The pharmaceutical composition of claim 9 or claim 10, wherein all or part of the population of antibodies comprise a heavy chain comprising a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence that is amidated.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein less than about 35% of the population of antibodies is singly amidated.

### Claim 14 (depends on 10)

The pharmaceutical composition of claim 10, wherein all or part of the population of antibodies comprise a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence in both heavy chains.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein all or part of the population of antibodies comprising two heavy chains comprising a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence are amidated on both heavy chains.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein less than about 35% of the population of antibodies are amidated on both heavy chains.

### Claim 17 (depends on 9, 10, 11, 12, 13, 14, 15, 16)

The pharmaceutical composition of any one of claims 9-16, wherein less than about 35% of the population of antibodies comprise heavy chains that are not amidated.

### Claim 18 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17)

The pharmaceutical composition of any one of claims 9-17, wherein about 33% of the population of antibodies are not amidated, about 33% of the population of antibodies comprise one amidated heavy chain, and about 33% of the population of antibodies comprise two amidated heavy chains.

### Claim 19 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The pharmaceutical composition of any one of claims 9-18, further comprising a calcium salt, an acetate buffer, a polyol and a surfactant.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the calcium salt comprises calcium acetate.

### Claim 21 (depends on 19)

The pharmaceutical composition of claim 19, wherein the acetate buffer comprises sodium acetate.

### Claim 22 (depends on 19)

The pharmaceutical composition of claim 19, wherein the polyol comprises sucrose.

### Claim 23 (depends on 19)

The pharmaceutical composition of claim 19, wherein the surfactant comprises polysorbate 20.

### Claim 24 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The pharmaceutical composition of claim any one of claims 9-23, further comprising 55 mM acetate, 13 mm calcium, 6.0% (w/v) sucrose, 0.006% (w/v) polysorbate 20, pH 5.2.

### Claim 25 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of increasing bone mineral density in a subject in need thereof comprising administering the composition of any one of claims 9-24 to the subject in an amount effective to increase bone mineral density in the subject.
